MedPath

ASTELLAS PHARMA EUROPE B.V.

🇪🇸Spain
Ownership
-
Employees
-
Market Cap
-
Website

A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo
First Posted Date
2012-06-05
Last Posted Date
2017-08-22
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
44
Registration Number
NCT01611363

Drug to Drug Interaction Study With Ipragliflozin and Furosemide

Phase 1
Completed
Conditions
Healthy Subjects
Pharmacokinetics of Ipragliflozin
Interventions
First Posted Date
2012-06-05
Last Posted Date
2012-06-05
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
24
Registration Number
NCT01611415

Absolute Bioavailability Study With Ipragliflozin

Phase 1
Completed
Conditions
Bioavailability of Ipragliflozin
Healthy Subjects
Interventions
First Posted Date
2012-06-05
Last Posted Date
2012-06-05
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
14
Registration Number
NCT01611428

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder

Phase 2
Completed
Conditions
Urinary Bladder, Overactive
Interventions
First Posted Date
2012-05-24
Last Posted Date
2024-10-31
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
260
Registration Number
NCT01604928
Locations
🇧🇪

Site: 12, Brussels, Belgium

🇧🇪

Site: 13, Edegem, Belgium

🇧🇪

Site: 11, Gent, Belgium

and more 27 locations

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Phase 1
Completed
Conditions
Pharmacokinetics
Healthy Subjects
Mild and Moderate Hepatic Impairment
Interventions
First Posted Date
2012-04-18
Last Posted Date
2013-09-05
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
32
Registration Number
NCT01579461
Locations
🇸🇰

FNsP Bratislava, nemocnica akad. L. Dérera; Klinika pracovného lekárstva a toxikológie, Bratislava, Slovakia

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

Phase 3
Completed
Conditions
Urinary Bladder, Overactive
Interventions
Drug: Placebo
Behavioral: Urotherapy
First Posted Date
2012-03-29
Last Posted Date
2024-10-31
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
189
Registration Number
NCT01565707
Locations
🇺🇸

Site: 1006, Shreveport, Louisiana, United States

🇺🇸

Site: 1015, Albany, New York, United States

🇧🇪

Site: 3202, Antwerp, Belgium

and more 43 locations

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Phase 3
Completed
Conditions
Neurogenic Detrusor Overactivity
Interventions
First Posted Date
2012-03-29
Last Posted Date
2024-11-14
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
76
Registration Number
NCT01565694
Locations
🇺🇸

Site US1008, Tarrytown, New York, United States

🇺🇸

Site US1010, Cincinnati, Ohio, United States

🇧🇪

Site BE3201, Gent, Belgium

and more 18 locations

To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis

Terminated
Conditions
Clostridium Difficile
First Posted Date
2012-02-15
Last Posted Date
2015-03-04
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
1
Registration Number
NCT01533844
Locations
🇫🇷

Site: 3301, Poissy, Paris, France

🇫🇷

Site: 3302, Lyon, France

🇩🇪

Site: 4902, Erlangen, Germany

and more 6 locations

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder

Phase 2
Completed
Conditions
Urologic Diseases
Urinary Bladder Diseases
Signs and Symptoms
Urinary Bladder, Overactive
Urological Manifestations
Interventions
First Posted Date
2011-04-21
Last Posted Date
2024-10-31
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
1307
Registration Number
NCT01340027
Locations
🇧🇾

BY37101, Minsk, Belarus

🇧🇾

BY37102, Minsk, Belarus

🇧🇾

BY37103, Minsk, Belarus

and more 130 locations
© Copyright 2025. All Rights Reserved by MedPath